Identity
Pfizer, S.L.U.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €156.0M | |
| 2025 | €169.3M | |
| 2024 | €92.8M | |
| + regional platforms | ||
| 2023 | €72.9M | |
| 2022 | €57.9M | |
| 2021 | €64.8M | |
| 2020 | €45.7M | |
| 2019 | €34.8M | |
| 2018 | €15.6M | |
| 2017 | €18.1M | |
| 2016 | €2.7M | |
In figures
Volume
Between 2016 and 2026 it won 1,332 contracts worth €730M on its own, with 68 buyers. Its 13 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 30.9%; the middle half of its discounts between 28.7% and 38.3% (7 comparable awards).
Competition
Since 2024, 85% of its comparable value was won with a discount and against other bidders. It was the only bidder in 87% of its contracts (2016–2026).
Renewals
99 contracts (€63.0M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Pfizer, S.L.U.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Pfizer, S.L.U.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 30.9% · middle half between 28.7% and 38.3% · 7 awards
2019–2026: median 28.9% · middle half between 8.8% and 39.0% · 23 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
732 contracts · €417M
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
6 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
85% of the comparable value since 2024 (€12.4M of €14.5M) was won with a discount and against other bidders. €1.30M (9%) was awarded at the tender price and without other bidders.
Comparable: 37 awards with a published budget and bidder count (€14.5M of €418M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 70.0% of the value was awarded through negotiated without publicity procedure (42.9% of contracts); followed by Based on a framework agreement (10.9%) and Open (8.8%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 99 of its contracts come up for tender again, worth €63.0M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | €54.1k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €46.2k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €17.7k |
| 2026 | Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | — |
| 2026 | Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | — |
and 94 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 23 | 98 M | 2024–2026 |
| Servicio Andaluz de Salud | 98 | 85 M | 2024–2026 |
| Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín | 512 | 66 M | 2018–2026 |
| Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | 71 | 65 M | 2020–2026 |
| Departament de Salut | 28 | 56 M | 2022–2026 |
and 63 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,311 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 03/07/2026 | Suministro De Medicamentos De Uso Humano Tipo Ii (Exclusivos), Con Destino Al Servicio De Farmacia … | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | 2 | €36.3k |
| 03/07/2026 | Suministro de medicamentos de uso humano exclusivos, con destino al servicio de farmacia del hospit… | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | 5 | €12.8k |
| 08/06/2026 | cpca 1º cbam pfizer, s.l. exp. 578/2025 suministro medicamento exclusivos cca: +6.i+e0q8j, am contr… | Servicio Andaluz de Salud | 1 | €335k |
| 27/04/2026 | Contrato basado en el AM INGESA 2025/034, para el suministro respetuoso con el medio ambiente de me… | Servicio Cántabro de Salud | 1 | €5.09k |
| 13/03/2026 | Suministro Farmacéutico de los Principios Activos Adalimumab (20,40 y 80), Trastuzumab (150 y 420 )… | Gerencia de Servicio Sanitarios de Fuerteventura | 1 | €17.7k |